

Institutional Research Ethics Committee

iics committee		
REC Form No.	6 (D)	
Version No:	02	
Date of Effectivity:		

Study Protocot Assessment Form				
STUDY PROTOCOL INFORMATI	ON			
Reference Number:1				
UPOU IREC Code:2				
Study Protocol Title:				
Principal Investigator:			e, Name, Surr	name>
Study Protocol Submission D	ate:	<dd <="" th=""><th>/mm/yyyy></th><th></th></dd>	/mm/yyyy>	
INSTRUCTIONS				
To the Principal	Does you	ur res	earch involve	human participants?
Investigator:		\/		·
		Yes		
		No		
	specified facilitate	d asse the e	ssment point evaluation of	e provided below whether or not the is addressed by your study protocol. To the assessment point, indicate the page nformation can be found.
To the Primary Reviewer:	Please evaluate how the assessment points outlined below have been appropriately addressed by the study protocol, as applicable, by confirming the submitted information and putting your comments in the space provided under "REVIEWER COMMENTS." Finalize your review by indicating your conclusions under "RECOMMENDED ACTION" and signing in space provided for the primary reviewer.			
ASSESSMENT POINTS	To be fill Indicate the stud protocol contains specified assessm point	if y the	Page and paragrap h where it is found	REVIEWER COMMENTS
1. SCIENTIFIC DESIGN	YES	N/A		
1.1. Objectives Review of viability of expected output 1.2. Literature review Review of results of previous animal/human studies showing known risks and benefits of				

¹ To be issued upon _____ registration ² To be issued upon initial processing by UPOU IREC



Institutional Research Ethics Committee

REC Form No.	6 (D)
Version No:	02
Date of Effectivity:	

intervention, including known adverse drug		
effects, in case of drug trials		
1.3. Research design		
Review of appropriateness		
of design in view of		
objectives		
1.4. Sampling design		
Review of appropriateness		
of sampling methods and		
techniques		
1.5. Sample size		
Review of justification of		
sample size		
1.6. Statistical analysis plan (SAP)		
Review of appropriateness		
of statistical methods to		
be used and how		
participant data will be		
summarized		
1.7. Data analysis plan		
Review of appropriateness		
of statistical and		
non-statistical methods of		
data analysis		
1.8. Inclusion criteria		
Review of precision of		
criteria both for scientific		
merit and safety concerns;		
and of equitable selection		
1.9. Exclusion criteria		
Review of criteria		
precision both for		
scientific merit and safety		
concerns; and of justified		
exclusion		
1.10. Withdrawal criteria		
Review of criteria		
precision both for		
scientific merit and safety		
concerns		
2. CONDUCT OF STUDY		
2.1. Specimen handling		



Institutional Research Ethics Committee

REC Form No.	6 (D)
Version No:	02
Date of Effectivity:	

Review of specimen storage, access, disposal, and terms of use 2.2. PI qualifications Review of CV and relevant certifications to ascertain capability to manage		
study related risks 2.3. Suitability of site Review of adequacy of qualified staff and		
infrastructures 2.4. Duration Review of length/extent of human participant involvement in the study		
ETHICAL CONSIDERATIONS		
2.5. Conflict of interest		
Review of management of		
conflict arising from		
financial, familial, or		
proprietary considerations		
of the PI, sponsor, or the		
study site		
2.6. Privacy and		
confidentiality		
Review of measures or		
guarantees to protect		
privacy and confidentiality		
of participant information		
as indicated by data		
collection methods		
including data protection		
plans		
2.7. Informed consent		
process		
Review of application of		
the principle of respect for		
persons, who may solicit		
consent, how and when it		
will be done; who may		
give consent especially in		
case of special		
populations like minors		
and those who are not		



Institutional Research Ethics Committee

REC Form No.	6 (D)
Version No:	02
Date of Effectivity:	

legally competent to give	
consent, or indigenous	
people which require	
additional clearances	
2.8. Vulnerability	
Review of involvement of	
vulnerable study	
populations and impact	
on informed consent (see	
3.3). Vulnerable groups	
include children, the	
elderly, ethnic and racial	
minority groups, the	
homeless, prisoners,	
people with incurable	
disease, people who are	
politically powerless, or	
junior members of a	
hierarchical group.	
Vulnerability must always	
be assessed in the context	
of the protocol and the	
participants.	_
2.9. Recruitment	
Review of manner of	
recruitment including	
appropriateness of	
identified recruiting	
parties 2.10. Assent	
Review of feasibility of	
obtaining assent vis à vis	
incompetence to consent;	
Review of applicability of	
the assent age brackets in	
children:	
0-under 7: No assent	
7-under 12: Verbal Assent	
12-under 15: Simplified	
Assent Form	
15-under 18:Co-sign	
informed consent form	
with parents	
211 Risks	



Institutional Research Ethics Committee

ines committee	
REC Form No.	6 (D)
Version No:	02
Date of Effectivity:	

Review of level of risk and measures to mitigate these risks (including physical ,psychological, social, economic), including plans for adverse event management; Review of justification for allowable use of placebo as detailed in the Declaration of Helsinki (as applicable) 2.12. Benefits Review of potential direct benefit to participants; the potential to yield generalizable knowledge about the participants' condition/problem; non-material compensation to participant (health education or other creative benefits), where no clear, direct benefit		
from the project will be received by the participant		
2.13. Incentives or		
compensation		
Review of amount and method of compensations, financial incentives, or reimbursement of		
study-related expenses		
2.14. Community		
considerations		
Review of impact of the		
research on the		
community where the		
research occurs and/or to		
whom findings can		
be linked; including issues		
like stigma or draining of		
local capacity; sensitivity		
to cultural traditions, and		



UP OPEN UNIVERSITY Institutional Research Ethics Committee

REC Form No.	6 (D)
Version No:	02
Date of Effectivity:	

involvement of the community in decisions about the conduct of study 2.15. Collaborative study terms of reference Review of terms of collaborative study especially in case of multi-country/multi-instit utional studies, including intellectual property rights, publication rights, information and responsibility sharing, transparency, and capacity building 2.16. Other issues		
w of issues not subsumed in		
the issues covered by items 3.1 to 3.11		
RECOMMENDED ACTION:		
☐ APPROVE		
☐ MINOR MODIFICATION	S	
☐ MAJOR MODIFICATION	S	
☐ DISAPPROVE		
☐ PENDING, IF MAJOR CL	ARIFICATIONS ARE	
REQUIRED BEFORE A D		ADE
JUSTIFICATION FOR RECOMMEN	IDED ACTION	
PRIMARY REVIEWER	Signature	
Date: <dd mm="" yyyy=""></dd>	Name	<title, name,="" surname=""></title,>